Retatrutide and trizepatide are a new class of medications that target both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These combined receptor agonists exhibit https://lexieudyq013728.aioblogs.com/91386362/recent-glp-1-and-gip-receptor-agonists-retatrutide-and-trizepatide